Shares of Biogen BIIB gained 9.5% on Dec 29 following news on its potential acquisition by the South-Korean conglomerate Samsung Group. Per an article in The Korean Economic Daily, the U.S.-based ...
On July 17, 2025, Harrow, Inc. (“Harrow”), announced an agreement with Samsung Bioepis Co. Ltd. (“Samsung Bioepis”) to acquire the U.S. commercial rights to two of Samsung Bioepis’s biosimilars, ...
Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ ®, a biosimilar to Lucentis 1 (ranibizumab), in Europe. Samsung Bioepis has been working to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results